Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Arcus Biosciences Inc (Arcus Biosciences) is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Its product pipeline includes Casdatifan (CAS) treats kidney cancer; Domvanalimab (DOM) targets gastrointestinal cancer and lung cancer; Quemliclustat (QUEMLI) for pancreatic cancer and lung cancer; Etrumadenant (ETRUMA) which targets colorectal cancer; AB598 for gastrointestinal cancer; and AB801 which treats lung cancer. The company operates it offices in Brisban and Hayward, California, the US. Arcus Biosciences is headquartered in Hayward, California, the US.
Headquarters
United States of America
Address
3928 Point Eden Way, Hayward, California, 94545-3719
Website
arcusbio.com
Telephone
1 510 6946200
No of Employees
601
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RCUS (NYSE)
Revenue (2024)
$247.0M
-4.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-24.7%
(2024 vs 2023)
Market Cap*
$3.7B
Net Profit Margin (2024)
XYZ
-30.3%
(2024 vs 2023)
* As of and is in US$
Arcus Biosciences Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Casdatifan (CAS): Kidney Cancer |
| Domvanalimab (DOM): Gastrointestinal Cancer and Lung Cancer |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In October, the company partnered with AstraZeneca to evaluate Arcus's casdatifan (HIF-2a inhibitor) with AstraZeneca’s volrustomig (PD-1/CTLA-4 bispecific antibody) in patients with ccRCC. |
| 2024 | Contracts/Agreements | In August, the company received a US$250 million term loan facility from Hercules Capital, Inc. to rapidly advance casdatifan, its potential best-in-class HIF-2a inhibitor. |
| 2024 | Contracts/Agreements | In June, the company in collaboration with Gilead Sciences completed patient enrollment for STAR-221, a Phase 3 study. |
Competitor Comparison
| Key Parameters | Arcus Biosciences Inc | Merck & Co Inc | Pfizer Inc | AstraZeneca Plc | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | Switzerland |
| City | Hayward | Rahway | New York City | Cambridge | Basel |
| State/Province | California | New Jersey | New York | Cambridgeshire | Basel-Stadt |
| No. of Employees | 601 | 75,000 | 75,000 | 96,100 | 75,267 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Terry Rosen, Ph.D | Chief Executive Officer; Chairman | Executive Board | 2017 | 66 |
| Robert C. Goeltz | Chief Financial Officer | Senior Management | 2020 | 53 |
| Jennifer Jarrett | Chief Operating Officer | Senior Management | 2020 | 55 |
| Alex Azoy | Chief Accounting Officer | Senior Management | - | - |
| Richard Markus, MD, PhD | Chief Medical Officer | Senior Management | 2025 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer